查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830374

器官晶片市场（按材料、产品、技术、最终用户、应用和器官类型）—2025-2032 年全球预测

Organs-on-chips Market by Material, Product, Technology, End User, Application, Organ Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，器官晶片市场规模将成长至 17.6249 亿美元，复合年增长率为 35.25%。

主要市场统计数据
基准年2024年 1.5736亿美元
预计2025年 2.1296亿美元
预测年份：2032年 17.6249亿美元
复合年增长率（%） 35.25%

简要概述器官晶片的演变、相关人员的优先事项以及将微生理系统整合到转化流程中的战略要务

随着器官晶片领域从学术上的好奇心逐渐发展成为一项能够在体外更精确地重现人体生理学的关键技术，本介绍将该技术纳入了研究机构和行业领导者的战略议程。早期研究着重于可行性论证，而如今的重点已转向可重复性、与标准化实验室工作流程的整合以及与下游研发和转换流程的兼容性。因此，开发者和采用者越来越多地评估平台，不仅关注其生物保真度，还关注其材料、可製造性和数据互通性。

玻璃、PDMS 和热塑性塑胶等材料的选择会影响设备的性能、可製造性和法规认可度，进而影响实验室和商业团队从原型製作到规模化生产的设计决策。耗材包括微孔盘和试剂等必需品，决定了每日实验通量和成本结构。技术模式涵盖微流体晶片（包括多层和单层晶片）到多器官和单器官晶片，从而支​​持从以器官为中心的研究到互联繫统级研究的广泛应用。

最终用户包括学术研究机构、生物技术公司、委外研发机构和製药公司，后者包括全球性和专业性製药公司，它们的风险接受度和采用时间表各不相同。常见应用包括疾病建模、高通量筛检和先导药物最适化的药物发现、个人化医疗和毒性测试。目前正在开发的器官类型包括肠道、心臟、肾臟、使用肝细胞和球状体策略的肝臟以及肺，每种器官类型都面临各自的生物学、分析和监管挑战。本引言透过强调优先事项的整合来构成执行摘要的其余部分：生物学相关性、工业扩充性以及与现有研发工作流程的整合。

快速的技术成熟、模组化整合以及不断变化的最终用户期望如何重塑器官晶片创新的采用途径和商业策略

器官晶片领域正在经历一场变革性的转变，其特点是技术日趋成熟、工作流程日趋整合，以及来自资助方和监管机构的期望不断演变；这些变化正在再形成其应用路径。如今，玻璃、PDMS 或热塑性塑胶的选择反映了生物相容性、光学透明度和生产扩充性之间的权衡取舍。因此，各公司正在重新评估其平台蓝图，优先考虑与自动化处理和成像系统的兼容性。

在产品策略方面，该行业正从孤立的仪器转向整合解决方案，将微孔盘和试剂等耗材与可互通的仪器和软体相结合，使最终用户能够以更少的内部工程开销部署工作流程。多层和单层晶片的流体控制和製造成本各不相同，多器官晶片为系统级药理学创造了机会，而单器官晶片则继续在重点机制研究中发挥作用。这种技术多样化伴随着学术机构、生物技术公司、合约研究组织和製药公司的深入参与（后者在全球製药和专业製药领域有不同的优先事项）。

应用领域正在同步扩充。虽然疾病建模和毒性测试仍然是核心，但药物研发工作流程越来越多地纳入针对器官特异性测量的高通量筛检和先导化合物优化步骤。个人化医疗正在利用器官特异性环境中的患者来源先导化合物，例如肠道、心臟、肾臟、透过基于肝细胞和球状体的肝臟系统进行的肝臟治疗以及肺部治疗，这重新引发了人们对捐赠多样性、细胞来源和标准化方案的关注。总的来说，这些转变强调了互通性、标准化和资料稳健性，这些标准将广泛采用的平台与小众的学术原型区分开来。

评估新推出的关税政策对供应链、采购决策以及研发时间表在 2025 年前的累积营运和策略影响

2025年高关税的实施迫使产业相关人员重新评估其供应链策略、采购时机以及零件和完整系统的地理采购决策，并将对整个价值链产生累积影响。许多设备製造商依赖专用组件，例如精密玻璃、PDMS和热塑性塑胶等聚合物基板、微加工工具以及外包计量模组。由于关税影响原材料和次组件的进口，製造商面临更高的到岸成本，这会影响定价、供应商选择和库存管理决策。因此，各团队正在部署对冲策略，例如多方采购、增加本地库存，以及在某些情况下将部分组装业务迁移到更靠近关键客户所在地的地方。

对于耗材（尤其是微孔盘和试剂），关税环境增强了试剂本地化生产或跨司法管辖区授权多家供应商的奖励，以避免单点故障。软体和数位交付物受关税的直接影响较小，但会因硬体发货和整合测试延迟而受到连锁反应。此外，依赖进口设备的合约研究组织和生物技术公司必须重新考虑计划预算和进度，将采购交付前置作业时间、海关变化以及潜在的重新测试纳入考量，以确保在重新采购组件时符合法规要求。

这些营运调整也影响着策略伙伴关係关係。为了减轻关税的影响，企业越来越愿意签订联合生产协议、建立策略采购联盟和区域分销合作伙伴关係。例如，替代材料或替代品的认证可能会触发额外的验证要求，尤其是对于依赖肝细胞或球状体系统的肝臟模型，这些系统必须证明其生物学性能。总而言之，关税变化的累积影响正在导致供应链设计更加复杂，但也更具弹性，加速了关于近岸外包、供应商多元化以及与製造商和经销商达成长期合约安排的讨论。

详细的細項分析揭示了材料、产品、技术、最终用户、应用和器官特定选择如何影响采用、检验和商业策略

特定细分市场的动态正在影响开发人员和买家对平台的优先排序，了解这些细微差别对于有效的产品组合管理至关重要。在玻璃、PDMS 和热塑性塑胶之间进行材料选择，不仅会影响装置性能，还会影响其对高内涵成像的光学适用性和生产可扩展性。玻璃具有优异的光学性能和耐化学性，但製造过程可能较为复杂，而 PDMS 则因其快速原型製作和透气渗透性而极具吸引力。

将产品细分为耗材、设备和软体，可以揭示不同的利润率、服务模式和客户互动。耗材包括微孔盘和试剂，它们会产生经常性收益，并且需要强大的供应链连续性。在技​​术选择方面，微流体晶片有多层和单层两种类型，它们在控制复杂性和製造简易性之间做出权衡；多器官晶片能够实现与全身药理学相关的新兴表型，而单器官晶片则支援有针对性的机制研究。

不同的最终用户有不同的采用行为：学术研究机构优先考虑假设驱动研究的灵活性和成本效益；生物技术公司优先考虑概念验证的速度和平台授权的可能性；委外研发机构优先考虑通量、可重复性和合规性；而製药公司（无论是全球性公司还是专业性公司）则透过产品组合的一致性、降低监管风险以及加快候选药物筛选的潜力来评估平台。应用驱动技术和营运需求。疾病建模和毒性测试需要生理保真度和检验的读数；高通量筛检和先导药物最适化等药物研发工作流程需要扩充性和自动化；个人化医疗依赖与患者来源细胞的兼容性。器官特异性细分（肠道、心臟、肾臟、采用肝细胞和球状体策略的肝臟以及肺部）进一步决定了细胞来源、检测方法开发和验证途径。整合这些细分视角，可以更精确地确定研发投资和商业性上市策略的优先顺序。

製造能力、法规环境和研究生态系统的地理差异如何影响全球商业化和供应链策略

区域动态从根本上影响供应链的韧性、监管方式和伙伴关係策略，了解地域差异对于部署和商业化计画至关重要。在美洲，製药和生物技术中心的强劲需求正在推动早期商业化，鼓励对本地组装的投资以及与契约製造製造商的合作，以降低跨境关税和运输中断带来的风险。该地区的学术研究中心和新兴企业持续为创新管道做出贡献，围绕生命科学投资的区域政策倡议正在鼓励转化合作，将设备开发人员与临床和临床前测试机构联繫起来。

在欧洲、中东和非洲，监管协调工作和强大的委外研发机构系统为标准化验证和合作研发计划创造了有利环境。欧洲研究联盟和专业製药公司通常强调可重复性和遵守严格的安全框架，这体现在其材料选择和设备合格策略中。有针对性的产学研合作以及对转化能力建设的投资正在推动中东和非洲的早期应用。

亚太地区呈现出多元化的格局，拥有强大的製造能力、广泛的热塑性零件供应链以及显着成长的生物技术新创公司。该地区强大的製造能力支持着耗材和设备的快速扩张，而领先的研究型大学和合约研究组织 (CRO) 则致力于推动药物研发、疾病建模和毒性评估等应用情境的发展。这些地理差异意味着企业必须根据区域优势自订其商业化和伙伴关係模式，在接近性最终用户与获得专业供应商和监管途径之间取得平衡。

透过消耗品、设备和软体、检验的工作流程和可製造材料的垂直整合的策略价值来体现竞争和伙伴关係动态

随着企业在设备工程、生物製药整合和软体分析方面的能力提升，器官晶片领域的竞争态势正在不断演变，策略差异化不再仅仅依赖单一技术优势，而是更依赖生态系统的编配。成熟企业和创新新兴企业都专注于垂直整合产品，将微孔盘和试剂等高品质耗材与强大的仪器和以数据为中心的软体相结合，从而降低最终用户的技术门槛，并创造持续的商机。

那些能够针对疾病建模和毒性测试等关键应用展示检验的工作流程，并能够定制玻璃、PDMS 和热塑性塑料等可製造性设备材料的组织，将更有能力与合约研究组织和製药公司建立战略伙伴关係关係。同样，那些能够提供灵活微流体架构，并平衡多层和单层晶片功能以及多器官和单器官配置的技术领导者，能够透过满足高通量发现需求和深入的机制研究来创造价值。诸如生物模型授权、试剂供应合作以及投资支持标准化数据收集和分析的软体平台等策略倡议，正在塑造竞争格​​局。

买方行为也青睐能够支援各种终端用户的供应商，从寻求经济高效且适应性强的系统的学术机构，到需要严格验证的全球製药公司，再到对利基应用感兴趣的专业製药公司。投资于监管专业知识、可扩展生产以及支援长期专案的服务基础设施的公司，更有可能提高客户维繫，并在各个应用领域获得更广泛的应用。

为高阶主管提供实用的策略和营运步骤，以加速采用、降低验证风险并建立有弹性且可扩展的晶片器官经营模式

行业领导者应采取一系列切实可行的措施，将技术能力与商业性和营运韧性相结合。首先，优先考虑平衡生物性能和可製造性的材料策略，在开发週期早期对玻璃、PDMS 和热塑性塑胶进行资格合格，以减少后期意外情况和检验负担。其次，设计产品蓝图，将微孔盘和试剂等耗材与仪器和软体集成，以创建无缝的工作流程。

第三，我们正在实现供应链多元化，并建立区域製造或组装选项，以降低关税相关风险和物流风险。同时，我们正在与主要供应商协商多年期合约，以确保关键耗材的连续性。第四，在技术开发中，我们保持模组化，以支援多层和单层晶片的变体，为多器官晶片整合提供途径，使客户能够从单器官研究扩展到系统级研究，而无需更换整个平台。第五，我们优先考虑最终用户的参与，为学术研究机构、生物技术公司、合约研发组织和製药公司开发客製化产品，并为全球和专业製药客户提供量身定制的服务和检验套件。

最后，为了支援高通量筛检和先导药物最适化等药物研发活动，以及疾病建模和个人化医疗应用，投资于能够实现可重复性、实验室间可比性以及与实验室资讯系统整合的数据标准和软体平台。这些措施结合，可以减少部署摩擦，并建立稳固的商业性地位。

采用严格的混合方法研究途径，结合相关人员访谈、技术评估和区域供应链分析，为实际部署和伙伴关係决策提供资讯

本研究采用混合方法，结合定性产业访谈、技术文献综述以及设备架构和供应链路径的比较分析，以确保科学、商业性和营运因素的平衡观点。透过与学术机构、生物技术公司、合约研究组织和製药公司的相关人员进行结构化访谈，收集了关键见解，提供了关于验证标准、采购惯例以及与现有研发工作流程整合的挑战的观点。

技术评估检视了玻璃、PDMS 和热塑性塑胶之间的材料特性差异，并评估了製造选择（例如多层晶片与单层晶片）如何影响可製造性和功能读出。评估还采用了实验室工作流程映射方法，以了解微孔盘和试剂等耗材如何与设备和软体交互，用于疾病建模、透过高通量筛检和先导药物最适化进行药物发现、个人化医疗和毒理学测试等应用。区域分析考虑了美洲、欧洲、中东和非洲以及亚太地区的製造能力、法律规范和生态系统成熟度，并重点关注了实际部署方面的考虑因素。

我们尽可能交叉引用公开的技术报告、专利态势和平台检验案例研究，以确保可靠性。在整个过程中，我们专注于识别营运限制和应用障碍，而不是预测量化的市场轨迹，这使我们能够为研发、商业和供应链领导者提供直接可行的建议。

关于技术严谨性、材料策略和供应链弹性如何决定器官晶片在研究和工业领域的应用速度和广度的关键要点

总而言之，器官晶片正在从实验平台转变为实用工具，对药物研发、毒性评估和个人化医疗途径产生重大影响，前提是开发商和采购者在可重复性、材料策略和整合能力方面达成协议。材料选择、设备架构和耗材生态系统之间的相互作用不仅会影响实验结果，还会影响该解决方案在不同终端用户中扩展和商业化的可行性。在开发早期解决供应链弹性和监管合格，将降低下游风险，并使合约研发机构和製药合作伙伴能够更可靠地采用该解决方案。

展望未来，那些提供经过验证的可互通解决方案并投资于软体和数据标准化的公司将能够抓住疾病建模、高通量筛检、先导药物最适化活动以及肠道、心臟、肾臟、基于肝细胞和球体的肝臟和肺部器官特定用例方面的机会。透过将严谨的技术与切合实际的商业化和采购策略相结合，相关人员可以在管理营运复杂性的同时加速产生影响。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合多器官晶片用于综合疾病建模和药物反应分析
  • 采用诱导性多功能干细胞模型在器官晶片平台中实现个人化医疗应用
  • 实施先进的微流体灌注系统，模拟组织晶片内的生理剪切应力和流体流动条件
  • 扩大高通量器官晶片筛检平台，加速临床前药物发现与毒性测试
  • 开发血管化器官晶片模型，真实模拟屏障功能和内皮细胞相互作用
  • 利用器官晶片技术评估奈米药物的传递和生物分布，用于标靶治疗
  • 将免疫系统组件整合到器官晶片设备中，以模拟发炎反应和免疫毒性评估
  • 器官晶片检验和商业化的法规结构和标准化工作的进展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 器官晶片市场（依材料）

  • 玻璃
  • PDMS
  • 热塑性塑料

9. 器官晶片市场（依产品）

  • 耗材
    • 微孔盘
    • 试剂
  • 装置
  • 软体

第 10 章 器官晶片市场（依技术）

  • 微流体晶片
    • 多层晶片
    • 单层晶片
  • 多重器官晶片
  • 单一器官晶片

第 11 章 器官晶片市场（依最终用户）

  • 学术机构
  • 生技公司
  • 合约研究组织
  • 製药公司
    • 全球製药公司
    • 专业製药公司

第十二章 器官晶片市场（依应用）

  • 疾病模型
  • 药物研发
    • 高通量筛检
    • 先导药物最适化
  • 个人化医疗
  • 毒性测试

第十三章 器官晶片市场（依器官类型）

  • 肠子
  • 心
  • 肾
  • 肝
    • 基于肝细胞
    • 球形底座
  • 肺

第十四章器官晶片市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章 器官晶片市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 器官晶片市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Emulate, Inc.
    • MIMETAS BV
    • TissUse GmbH
    • CN Bio Innovations Ltd.
    • InSphero AG
    • Nortis, Inc.
    • Hµrel Corporation
    • Tara Biosystems, Inc.
    • AxoSim LLC
    • Kirkstall Ltd
Product Code: MRR-431C35F6C22A

The Organs-on-chips Market is projected to grow by USD 1,762.49 million at a CAGR of 35.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 157.36 million
Estimated Year [2025] USD 212.96 million
Forecast Year [2032] USD 1,762.49 million
CAGR (%) 35.25%

A concise overview of organs-on-chips evolution, stakeholder priorities, and the strategic imperative for integrating microphysiological systems into translational pipelines

The organs-on-chips field has matured from academic curiosity to a pivotal technology enabling closer replication of human physiology outside the body, and this introduction situates the technology within the strategic agendas of research institutions and industry leaders. Early work focused on demonstrating feasibility; today emphasis has shifted toward reproducibility, integration with standardized laboratory workflows, and compatibility with downstream discovery and translational pipelines. As a result, developers and adopters increasingly evaluate platforms not only for biological fidelity but also for materials, manufacturability, and data interoperability.

Across laboratories and commercial teams, material choices such as Glass, PDMS, and Thermoplastics drive device performance, manufacturability, and regulatory acceptability, shaping design decisions from prototyping through scaled production. Concurrently, the product landscape spans Consumables, Instruments, and Software; consumables encompass essential items including Microplates and Reagents that determine day-to-day experiment throughput and cost structure. Technology modalities vary from Microfluidic Chips, which include both Multi Layer Chips and Single Layer Chips, to Multi Organ Chips and Single Organ Chips, enabling applications that range from focused organ studies to interconnected system-level investigations.

End users span Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter of which includes both Global Pharma and Specialty Pharma entities with differing risk tolerances and adoption timelines. Common applications include Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization activities, Personalized Medicine, and Toxicity Testing. Organ types addressed in current development efforts include Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung, each presenting distinct biological, analytical, and regulatory challenges. This introduction frames the remainder of the executive summary by highlighting the converging priorities of biological relevance, industrial scalability, and integration into established R&D workflows.

How rapid technological maturation, modular integration, and changing end-user expectations are reshaping adoption pathways and commercial strategies in organ-on-chip innovation

The organs-on-chips landscape is undergoing transformative shifts characterized by technological maturation, consolidation of workflows, and evolving expectations from funders and regulators, and these changes are reshaping adoption pathways. New fabrication approaches and materials science innovations have reduced the gap between prototyping and manufacturable devices; the choice between Glass, PDMS, and Thermoplastics now reflects a deliberate trade-off among biological compatibility, optical clarity, and production scalability. As a result, organizations are re-evaluating platform roadmaps to prioritize compatibility with automated handling and imaging systems.

In product strategy, the industry is moving beyond siloed instruments toward integrated solutions that pair consumables such as Microplates and Reagents with interoperable Instruments and Software, enabling end users to deploy workflows with less in-house engineering overhead. The microfluidic technology base itself is diversifying; Multi Layer Chips and Single Layer Chips offer different fluidic control and fabrication cost profiles, while Multi Organ Chips create opportunities for system-level pharmacology and single organ chips retain roles in focused mechanistic studies. This technological diversification is accompanied by deeper engagement from Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter with distinct priorities between Global Pharma and Specialty Pharma players.

Applications are broadening in parallel: Disease Modeling and Toxicity Testing remain core, while Drug Discovery workflows increasingly incorporate High Throughput Screening and Lead Optimization stages tailored to organ-specific readouts. Personalized Medicine initiatives are leveraging patient-derived cells in organ-specific contexts like Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based liver systems, and Lung, driving renewed attention to donor variability, cell sourcing, and standardized protocols. These shifts collectively emphasize interoperability, standardization, and data robustness as the criteria that will separate widely adopted platforms from niche academic prototypes.

An assessment of the cumulative operational and strategic effects of newly implemented tariff policies on supply chains, sourcing decisions, and R&D timelines in 2025

The introduction of elevated tariff measures in 2025 has compelled industry participants to reassess supply chain strategies, procurement timing, and geographic sourcing decisions for components and finished systems, and these effects are cumulative across the value chain. Many device makers rely on specialized components, including precision glass, polymer substrates such as PDMS and thermoplastic resins, microfabrication tooling, and outsourced instrumentation modules. When tariffs affect imports of raw materials or subassemblies, manufacturers confront higher landed costs that influence decisions about pricing, vendor selection, and inventory management. Consequently, teams are deploying hedging strategies, including multi-sourcing, increased local stocking, and in some cases, partial relocation of assembly activities closer to key customer bases.

For consumables-Microplates and Reagents in particular-the tariff environment has amplified incentives to localize reagent production or to qualify multiple suppliers across jurisdictions to avoid single points of failure. Software and digital deliverables are less directly impacted by tariffs but encounter knock-on effects through delays in hardware shipments and integration testing, which in turn affect project timelines for instrument-based deployments. In addition, Contract Research Organizations and biotechnology firms that depend on imported instrumentation have had to revisit project budgets and timelines to incorporate procurement lead times, customs clearance variability, and potential retesting to ensure regulatory compliance when components are re-sourced.

These operational adjustments are also influencing strategic partnerships. Companies are increasingly open to co-manufacturing agreements, strategic sourcing alliances, and regional distribution partnerships to mitigate tariff exposure. Regulatory considerations intersect with trade policy; for example, qualification of alternative materials or substitutes may trigger additional validation requirements, particularly for liver models that depend on Hepatocyte Based or Spheroid Based systems where biological performance must be demonstrated. In sum, the cumulative impact of tariff changes has led to more resilient, albeit more complex, supply chain designs and has accelerated conversations about nearshoring, supplier diversification, and long-term contractual arrangements with manufacturers and distributors.

Detailed segmentation analysis revealing how material, product, technology, end-user, application, and organ-specific choices influence adoption, validation, and commercial strategy

Segment-specific dynamics shape how developers and purchasers prioritize platforms, and understanding these nuances is essential for effective portfolio management. Material choices among Glass, PDMS, and Thermoplastics influence not only device performance but also optical compatibility for high-content imaging and the feasibility of scaling production. Glass offers excellent optical properties and chemical resistance but can raise fabrication complexity; PDMS remains attractive for rapid prototyping and gas permeability, whereas Thermoplastics provide industrial manufacturability and lower per-unit costs when volumes justify tooling investments.

Product segmentation into Consumables, Instruments, and Software highlights differing margins, service models, and customer interactions. Consumables, which include Microplates and Reagents, generate recurring revenue and require robust supply chain continuity; Instruments demand higher upfront investment and are often paired with long-term service contracts; Software enables data standardization, analytics, and integration with laboratory information management systems, influencing stickiness and cross-sell potential. Within technology choices, Microfluidic Chips present both Multi Layer Chips and Single Layer Chips variants that trade off control complexity against ease of manufacture, while Multi Organ Chips enable emergent phenotypes relevant to systemic pharmacology and Single Organ Chips support targeted mechanistic studies.

End users exhibit distinct adoption behaviors: Academic Institutes prioritize flexibility and cost-effectiveness for hypothesis-driven research; Biotechnology Companies emphasize speed to proof-of-concept and potential for platform licensing; Contract Research Organizations focus on throughput, repeatability, and compliance; Pharmaceutical Companies, whether Global Pharma or Specialty Pharma, evaluate platforms through the lens of portfolio alignment, regulatory risk reduction, and potential to accelerate candidate selection. Applications drive technical and operational requirements: Disease Modeling and Toxicity Testing demand physiological fidelity and validated readouts, Drug Discovery workflows such as High Throughput Screening and Lead Optimization require scalability and automation, and Personalized Medicine depends on compatibility with patient-derived cells. Organ-specific considerations-Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung-further determine cell sourcing, assay development, and validation pathways. Integrating these segmentation lenses enables more precise prioritization of R&D investment and commercial go-to-market tactics.

How geographic differences in manufacturing strength, regulatory environments, and research ecosystems shape commercialization and supply chain strategies globally

Regional dynamics fundamentally influence supply chain resilience, regulatory approaches, and partnership strategies, and understanding geographic variation is critical for deployment and commercialization plans. In the Americas, strong demand from established pharmaceutical and biotechnology hubs is driving early commercial uptake, supporting investments in localized assembly and partnerships with contract manufacturers to reduce exposure to cross-border tariffs and shipping disruptions. Academic research centers and startups in the region continue to contribute to innovation pipelines, and regional policy initiatives around life sciences investment are encouraging translational collaborations that connect device developers with clinical and preclinical testing sites.

In Europe, Middle East & Africa, regulatory harmonization efforts and a robust ecosystem of contract research organizations create an environment favorable to standardized validation and collaborative development projects. European research consortia and specialty pharma players often emphasize reproducibility and compliance with stringent safety frameworks, which inform material selection and device qualification strategies. Across the Middle East and Africa, nascent adoption is driven by targeted academic-industry partnerships and investments in translational capacity-building.

Asia-Pacific presents a diverse landscape, with strong manufacturing capabilities, extensive supply chains for thermoplastic components, and significant growth in biotechnology entrepreneurship. The region's manufacturing depth supports rapid scaling of consumables and instruments, while major research universities and CROs foster use cases in Drug Discovery, Disease Modeling, and toxicity assessment. These geographic differences mean that companies must tailor commercialization and partnership models to regional strengths, balancing proximity to end users with access to specialized suppliers and regulatory pathways.

Competitive and partnership dynamics driven by vertical integration of consumables, instrumentation, and software, and the strategic value of validated workflows and manufacturable materials

Competitive dynamics in the organs-on-chips domain are evolving as companies refine capabilities across device engineering, biologics integration, and software analytics, and strategic differentiation increasingly rests on ecosystem orchestration rather than single-technology advantage. Leading firms and innovative startups alike are focusing on vertically integrated offerings that combine high-quality consumables such as Microplates and Reagents with robust Instruments and data-centric Software, which together lower the technical entry barrier for end users and create recurring revenue opportunities.

Organizations that can demonstrate validated workflows for critical applications such as Disease Modeling and Toxicity Testing, and who can align device materials with manufacturability considerations spanning Glass, PDMS, and Thermoplastics, are better positioned to secure strategic partnerships with Contract Research Organizations and pharmaceutical partners. Similarly, technology leaders who offer flexible microfluidic architectures-balancing Multi Layer Chips and Single Layer Chips capabilities along with Multi Organ and Single Organ configurations-create value by addressing both high-throughput discovery requirements and detailed mechanistic studies. Strategic moves such as licensing biological models, forming reagent supply alliances, and investing in software platforms that enable standardized data capture and analytics are shaping the competitive landscape.

Buy-side behavior also favors providers that can support varied end users, from Academic Institutes seeking cost-effective, adaptable systems to Global Pharma requiring rigorous validation and Specialty Pharma interested in niche applications. Companies that invest in regulatory expertise, scalable manufacturing, and service infrastructures to support long-term programs will likely see higher customer retention and broader adoption across application domains.

Practical strategic and operational steps for executives to accelerate adoption, reduce validation risk, and build resilient, scalable organ-on-chip business models

Industry leaders should pursue a set of pragmatic, actionable measures that align technological capability with commercial and operational resilience, and these moves will accelerate adoption while managing execution risk. First, prioritize material strategies that balance biological performance and manufacturability by qualifying Glass, PDMS, and Thermoplastic options early in development cycles to reduce late-stage surprises and validation burdens. Second, design product roadmaps that integrate Consumables like Microplates and Reagents with Instruments and Software to create seamless workflows; bundling consumables with instruments can improve lifecycle economics and strengthen customer relationships.

Third, diversify supply chains and establish regional manufacturing or assembly options to mitigate tariff-related and logistical risks, while negotiating multi-year agreements with key suppliers to secure continuity for critical consumables. Fourth, in technology development, maintain modularity that supports both Multi Layer Chips and Single Layer Chips variants and offers pathways to Multi Organ Chips integration, so customers can scale from single-organ studies to system-level investigations without wholesale platform replacement. Fifth, prioritize end-user engagement by developing tailored offerings for Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with distinct service and validation packages for Global Pharma and Specialty Pharma customers.

Finally, invest in data standards and software platforms that enable reproducibility, cross-lab comparability, and integration with laboratory information systems to support Drug Discovery activities such as High Throughput Screening and Lead Optimization, as well as Disease Modeling and Personalized Medicine applications. Taken together, these steps will reduce adoption friction and create defensible commercial positions.

A rigorous mixed-methods research approach combining stakeholder interviews, technical assessments, and regional supply chain analysis to inform practical deployment and partnership decisions

This research employed a mixed-methods approach that combined qualitative industry interviews, technical literature review, and comparative analysis of device architectures and supply chain pathways, ensuring a balanced view of scientific, commercial, and operational factors. Primary insights were gathered through structured interviews with stakeholders spanning Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, which provided perspectives on validation criteria, procurement practices, and integration challenges with existing R&D workflows.

Technical assessment examined differences in material properties among Glass, PDMS, and Thermoplastics and evaluated how fabrication choices such as Multi Layer Chips versus Single Layer Chips influence manufacturability and functional readouts. The methodology also included laboratory workflow mapping to understand how Consumables including Microplates and Reagents interface with Instruments and Software across applications like Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization, Personalized Medicine, and Toxicity Testing. Regional analysis considered manufacturing capabilities, regulatory frameworks, and ecosystem maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific to highlight pragmatic deployment considerations.

Where possible, findings were triangulated against publicly available technical reports, patent landscapes, and case studies of platform validation to ensure reliability. Throughout the process, emphasis was placed on identifying operational constraints and adoption barriers rather than projecting quantitative market trajectories, enabling recommendations that are directly actionable for R&D, commercial, and supply chain leaders.

Key takeaways on how technical rigor, materials strategy, and supply chain resilience determine the pace and breadth of organs-on-chips adoption in research and industry

In conclusion, organs-on-chips are transitioning from experimental platforms to practical tools that can materially influence drug discovery, toxicity assessment, and personalized medicine pathways, provided developers and buyers align on reproducibility, materials strategy, and integration capabilities. The interplay between material selection, device architecture, and consumable ecosystems shapes not only experimental outcomes but also the feasibility of scaling and commercializing solutions across diverse end users. Addressing supply chain resilience and regulatory qualification early in development reduces downstream risk and enables more reliable adoption by Contract Research Organizations and pharmaceutical partners.

Looking forward, companies that deliver validated, interoperable solutions and invest in software and data standardization will capture opportunities across Disease Modeling, High Throughput Screening and Lead Optimization activities, and organ-specific use cases in Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based systems, and Lung. By integrating technical rigor with pragmatic commercialization and sourcing strategies, stakeholders can accelerate impact while managing operational complexity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multi-organ chips for comprehensive disease modeling and drug response analysis
  • 5.2. Adoption of human-derived induced pluripotent stem cell models for personalized medicine applications in organ-on-chip platforms
  • 5.3. Implementation of advanced microfluidic perfusion systems to mimic physiological shear stress and fluid flow conditions in tissue chips
  • 5.4. Expansion of high-throughput organ-on-chip screening platforms for accelerated preclinical drug discovery and toxicity testing
  • 5.5. Development of vascularized organ-on-chip models to simulate realistic barrier functions and endothelial interactions
  • 5.6. Utilization of organ-on-chip technology for evaluating nanomedicine delivery and biodistribution in targeted therapies
  • 5.7. Incorporation of immune system components in organ-on-chip devices to recreate inflammatory responses and immunotoxicity assessments
  • 5.8. Regulatory framework advancements and standardization initiatives for organ-on-chip validation and commercialization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organs-on-chips Market, by Material

  • 8.1. Glass
  • 8.2. PDMS
  • 8.3. Thermoplastics

9. Organs-on-chips Market, by Product

  • 9.1. Consumables
    • 9.1.1. Microplates
    • 9.1.2. Reagents
  • 9.2. Instruments
  • 9.3. Software

10. Organs-on-chips Market, by Technology

  • 10.1. Microfluidic Chips
    • 10.1.1. Multi Layer Chips
    • 10.1.2. Single Layer Chips
  • 10.2. Multi Organ Chips
  • 10.3. Single Organ Chips

11. Organs-on-chips Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies
    • 11.4.1. Global Pharma
    • 11.4.2. Specialty Pharma

12. Organs-on-chips Market, by Application

  • 12.1. Disease Modeling
  • 12.2. Drug Discovery
    • 12.2.1. High Throughput Screening
    • 12.2.2. Lead Optimization
  • 12.3. Personalized Medicine
  • 12.4. Toxicity Testing

13. Organs-on-chips Market, by Organ Type

  • 13.1. Gut
  • 13.2. Heart
  • 13.3. Kidney
  • 13.4. Liver
    • 13.4.1. Hepatocyte Based
    • 13.4.2. Spheroid Based
  • 13.5. Lung

14. Organs-on-chips Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Organs-on-chips Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Organs-on-chips Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emulate, Inc.
    • 17.3.2. MIMETAS B.V.
    • 17.3.3. TissUse GmbH
    • 17.3.4. CN Bio Innovations Ltd.
    • 17.3.5. InSphero AG
    • 17.3.6. Nortis, Inc.
    • 17.3.7. Hµrel Corporation
    • 17.3.8. Tara Biosystems, Inc.
    • 17.3.9. AxoSim LLC
    • 17.3.10. Kirkstall Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ORGANS-ON-CHIPS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ORGANS-ON-CHIPS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORGANS-ON-CHIPS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. EUR